US FDA Nod GSK's Gepotidacin NDA for Treating Urinary Tract Infections

GSK plc reported that the NDA for gepotidacin, a new oral antibiotic for treating female adults and adolescents with uUTIs, has been accepted by the US FDA. The FDA has decided to give Priority Review to this application and has set a PDUFA action...

OKYO Pharma Announces Start of Phase 2 Trial For Neuropathic Corneal Pain

OKYO Pharma Limited, a company in the clinical stage of biopharmaceutical development, is creating new treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP). This billion-dollar market lacks FDA-approved therapy for...

Circle Pharma Declares First Patients Dosed in Phase 1 Clinical Trial

Circle Pharma, Inc., a company focused on finding and creating new macrocycle therapies, disclosed that the initial group of patients has been given doses in the phase 1 study of CID-078, their groundbreaking oral cyclin A/B RxL inhibitor...

Bayer Seeks EMA Approval for Elinzanetant to treat vasomotor symptoms

The biotechnology firm Bayer has requested approval from the European Medicines Agency (EMA) for elinzanetant to treat moderate to severe vasomotor symptoms (VMS, commonly known as hot flashes) linked to menopause or triggered by adjuvant...

Ampath and Innocent Hearts Hospital Partner to expand diagnostic services

American Institute of Pathology & Laboratory Sciences Pvt Ltd (Ampath) in collaboration with Innocent Hearts Superspeciality Hospital expands its diagnostic services in Jalandhar with the launch of a new state-of-the-art pathology laboratory...

USV Launces OnArni for management of heart failure

USV Pvt. Ltd. has launched OnArni, a combination of Sacubitril and Valsartan, for treating heart failure, available at an affordable price of Rs. $8 is the cost for each tablet of 50mg. This affordable solution helps tackle the increasing...

India Hikes Drug Prices by 50% to Ensure Availability of Key Medicines

India's drug pricing regulator has raised the maximum price of 11 scheduled formulations by 50% to guarantee their accessibility. The majority of these medications are commonly used as initial treatment options for a range of conditions such as...

Metropolis Healthcare to Tap into Tier II and Tier III Cities

In a bid to expand its reach into underserved markets, Indian diagnostics chain Metropolis Healthcare is enhancing its presence across North and East India by establishing 25 new laboratories and 500 centres in Tier III cities. “We have expanded o...

Arbele and BioAI Health Ink pact to develop prototype

Arbele, a leading innovator in biopharmaceutical and biotechnology focused on targeting cadherin-17 (CDH17), has announced a strategic collaboration in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of...

India's Pharma Market Accounted over 5% growth in Sept 2024

The Indian pharmaceutical market (IPM) experienced a 5.3% growth in September this year, fueled by significant therapies demonstrating favorable value growth, reported by Pharmarack. Urology, cardiac, and dermatology treatments experienced close...

© 2024 India Pharma Outlook. All Rights Reserved.